This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Oncology Training and Resources

KEYTRUDA® (pembrolizumab)

KEYTRUDA® (pembrolizumab) resources

Prescribing Information

KEYTRUDA® (pembrolizumab) in advanced non-small cell lung cancer (NSCLC) resources

Prescribing Information

KEYTRUDA® (pembrolizumab) in advanced urothelial carcinoma resources

Prescribing Information

KEYTRUDA® (pembrolizumab) in advanced renal cell carcinoma (aRCC) resources

Prescribing Information

KEYTRUDA® (pembrolizumab) in first-line head & neck squamous cell carcinoma (HNSCC) resources

Prescribing Information

KEYTRUDA® (pembrolizumab) in advanced melanoma resources

Prescribing Information

LENVIMA® (lenvatinib)

LENVIMA® (lenvatinib) resources

Prescribing Information

LYNPARZA (olaparib)

LYNPARZA (olaparib) resources

Prescribing Information

LYNPARZA (olaparib) in ovarian cancer resources

Prescribing Information

ONCOTICE® (2-8 x 108 CFU Tice BCG)

ONCOTICE® (2-8 x 108 CFU Tice BCG) resources

Prescribing Information

Supporting documentation

KEYTRUDA® (pembrolizumab)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet


LENVIMA® 4 mg hard capsules
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

LENVIMA® 10 mg hard capsules
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet


LYNPARZA (olaparib) 100 mg and 150 mg film coated tablets
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

LYNPARZA (olaparib) 50 mg hard capsules
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet


ONCOTICE® (2-8 x 108 CFU Tice BCG)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-01124 | Date of Preparation: September 2020